Direct answer: Imagia refers to (at least) two different tech companies in public sources — one is a deep‑tech metasurface/optics startup (Imagia, founded ~2019, based in California) building “Processing Optics™” for ultra‑low‑power, in‑optics feature detection, and the other is a Canadian AI‑in‑healthcare company (Imagia, founded ~2012–2015) focused on medical imaging and precision‑medicine platforms (EVIDENS™); both appear in investor/press databases and should not be conflated.[1][3][2][6][5]
High‑Level Overview
- Imagia (optics/metasurfaces): A deep‑tech materials + photonics startup developing metasurface metalenses and arrays of microscopic optical filters called Processing Optics™ that implement mathematical convolutions optically to detect features (hands, faces, gestures) at light‑speed with very low power and very low latency, targeting computer‑vision and embedded camera applications.[1][3][4]
- Imagia (AI in healthcare): A Montreal‑area AI for healthcare company building an AI platform (EVIDENS™) to layer actionable machine‑learning insights on medical imaging and clinical data to support diagnostics, treatment selection and clinical research; it works with hospitals, pharma and research consortia on precision‑medicine projects.[2][5][6]
Origin Story
- Imagia (optics/metasurfaces): Founded around 2019 from metamaterials/metalens research; the team matured metalens fabrication (CMOS‑compatible metasurfaces) and extended the work to hard‑coded optical convolutions to move image processing into the optics themselves; the company has raised a seed round (~US$4.5M) to develop first‑generation planar silicon lenses and Processing Optics™.[1][3][4]
- Imagia (healthcare AI): Founded by Alexandre Le Bouthillier and Nicolas Chapados (with ties to Yoshua Bengio) in the 2010s (sources cite 2012–2015) to apply AI to medical discovery and precision medicine; they developed the EVIDENS™ platform and joined large Canadian health data/AI consortia, gaining early traction via hospital partnerships and government‑backed projects.[2][6][5]
Core Differentiators
- Optics/metasurface Imagia:
- Processing Optics™: optical filters that perform convolutional feature detection in the light path, reducing downstream compute need and latency dramatically (claimed ~500× latency reduction and <1% power of conventional approaches in demonstrations).[1][3]
- CMOS‑compatible fabrication: metasurfaces fabricated with semiconductor processes (scalability and integration with camera stacks).[1][3]
- Demonstrated extreme sparsity: prototypes reportedly detect hand/gesture with only a few pixels and microsecond‑scale response times, enabling very low‑power always‑on sensing.[1][3]
- Healthcare AI Imagia:
- Clinically focused ML: platform (EVIDENS™) designed to integrate imaging + clinical data to produce explainable, clinically actionable outputs for oncology and related areas.[2][5]
- Consortium and hospital partnerships: participation in national precision‑medicine initiatives and deployment in Quebec hospitals suggest domain credibility and access to real clinical datasets.[2][5]
- Team + academic links: founders and collaborators with strong academic AI ties (notably connection to Yoshua Bengio) that help with algorithmic credibility and research collaborations.[2]
Role in the Broader Tech Landscape
- Optics/metasurface Imagia rides multiple converging trends: the push to embed intelligence at the sensor (edge AI), demand for ultra‑low‑power always‑on sensing in IoT and AR/VR, and advances in nanofabrication/metasurfaces that let optical elements implement functions previously done in software; timing matters because power and latency constraints are increasingly central for wearables, robotics and privacy‑sensitive sensors (doing detection in‑optics can limit raw image capture and data transmission).[1][3][4]
- Healthcare AI Imagia fits the trend of translating deep learning into clinical workflows and precision medicine, where access to curated clinical imaging and explainable models determines adoption; national digital health programs and increasing regulatory clarity for AI in medicine create both opportunity and higher standards for clinical validation and partnerships.[2][5][6]
Quick Take & Future Outlook
- Optics/metasurface Imagia: Near term, expect productization of Processing Optics™ for niche embedded camera markets (gesture sensing, wearables, drones, low‑power IoT). Key milestones to watch: wafer‑scale manufacturing yields, integration with camera modules, and commercial design wins with device OEMs or AR/VR suppliers; longer term, if optics can reliably encode more complex feature maps, they could displace portions of the neural‑network inference stack for constrained devices, but that requires broad validation and developer tooling to make the optical “models” usable across applications.[1][3][4]
- Healthcare AI Imagia: Short term, continued deployment in hospital partners, clinical validation studies and integration with pharma/research consortia will determine commercial traction; regulatory acceptance and demonstrable clinical outcome improvements will shape scaling. Their influence could grow substantially if EVIDENS™ demonstrably improves trial outcomes or treatment selection at scale, but success depends on data access, rigorous validation, and adoption by clinical workflows.[2][5][6]
If you want, I can:
- Produce a one‑page investor‑style snapshot for either company (metrics, funding, key milestones).
- Compile press releases, patents and published papers to verify technical claims (optics/metasurfaces) or clinical studies (EVIDENS™).
- Map potential customers and competitors in either space.
Sources cited above correspond to public company profiles and press coverage for each Imagia instance: CB Insights/zoominfo/businesswire for the metasurface/Processing Optics company,[1][4][3] and company profiles/feature stories and BDC portfolio information for the Canadian healthcare AI company.[2][6][5]
